Services on Demand
Journal
Article
Indicators
- Cited by SciELO
- Access statistics
Related links
- Similars in SciELO
Share
Medicina interna de México
Print version ISSN 0186-4866
Abstract
GODINEZ-BACA, LE. and LUNA-PEREZ, D.. Early death risk stratification in post-myocardial infarction patients based on plasma copeptin levels. Med. interna Méx. [online]. 2017, vol.33, n.6, pp.754-763. ISSN 0186-4866. https://doi.org/10.24245/mim.v33i6.1222.
BACKGROUND:
Copeptin is a novel biomarker that has demonstrated good diagnostic performance in the early diagnosis of patients with acute coronary syndrome; however, its prognostic performance in the short-term survival (28 days) has not been established.
OBJECTIVE:
To determine the prognostic performance of copeptin for 28 day-mortality in patients with acute coronary syndrome.
MATERIAL AND METHOD:
A prospective, observational cohort of patients with acute coronary syndrome was done from January 1st 2014 to November 30 2015, measuring copeptin at presentation, registering deaths and event-free survivors over 28 days.
RESULTS:
Thirty-four patients were included, stratified as having low risk of death if copeptin was ≤ 12 pmol/L, intermediate risk between 12.1 and 32.5 pmol/L, and high risk ≥ 32.5 pmol/L, with a mortality of 0%, 15% and 30%, respectively; hazard ratio between high and low adjusted to confuse factors of 15.9 (CI95% 1.3-190; p = 0.02, Cox multivariable regression model).
CONCLUSION:
Elevated concentrations of copeptin are directly proportional to a higher risk of all-cause mortality, hence it could be used as a prognostic marker.
Keywords : copeptin; acute coronary syndrome; mortality; prognostic marker.